Life Sciences

Takeda Bags FDA Approval For Esophagus Inflammation The...

The U.S. Food and Drug Administration (FDA) has given the green light to Eohilia...

Trial for Gritstone’s BARDA-funded COVID-19 vaccine del...

Gritstone Bio has secured a substantial sum of $433 million in federal funding e...

Biotech Firm LianBio Announces Winding Down Operations

LianBio, a significant player in the biotech industry based in Shanghai, has rec...

CSL Behring’s major trial ends in disappointment After ...

CSL Behring, a prominent player in the Australian pharmaceutical landscape, rece...

Novo set to acquire Catalent plant for $16.5B

In November, regulators overseeing pharmaceutical standards in the U.S. identifi...

In an attempt to treat liver illness, Gilead buys CymaB...

Gilead Sciences has agreed to purchase CymaBay Therapeutics for $4.3 billion, ai...

Unlearn Secures $50 Million in latest funding round

Unlearn, a developer specializing in digital replicas, recently disclosed its at...

J&J’s Autoimmune Drug Prospect Meets Phase 3 Goal, Inch...

Johnson & Johnson’s recent triumph with its $6.5 billion autoimmune medication i...

Novartis spends €2.7 billion on acquiring MorphoSys

The recent buzz surrounding a potential bidding war for the cancer specialist Mo...

Gene therapy helps five out of six deaf children regain...

A Chinese biotechnology company’s experimental gene therapy has demonstrated enc...

Tecartus Labeling Update Causes Momentary Confusion in ...

In an unforeseen development, the FDA’s directive for a labeling alteration conc...

Novo Nordisk increase supply of Wegovy

Novo Nordisk has announced its highest annual profit in decades, attributing it ...

Defender Pharmaceuticals Confronts FDA Setback in Appro...

Defender Pharmaceuticals, headquartered in St. Louis, faces a setback in its que...

Sarepta’s DMD Drug Off to a Solid Start But Elevidys Pr...

It appears that Sarepta Therapeutics’ upcoming treatment for Duchenne muscular d...

Major trial testing shows a reduction in pain by using ...

A non-opioid pain reliever has demonstrated efficacy in two extensive clinical t...

Novo Nordisk stakes $255 million to acquire another obe...

Novo Nordisk has signed a partnership with EraCal Therapeutics, a Swiss biotech ...